Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Gland Pharma Limited Capital/Financing Update 2021

Feb 6, 2021

59319_rns_2021-02-06_55fe4151-33e1-4462-872e-9b871626ba98.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [59 x 48] intentionally omitted <==

==> picture [298 x 20] intentionally omitted <==

February 6, 2021

BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25[th] floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip Code: 543245 Symbol : GLAND (ISIN : INE068V01023)

Sub: Intimation of Schedule of Analyst / Institutional Investor Meetings

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find below the details of Investor Conferences the Company plan to attend during the month of February 2021:

Date Analyst/ Investor Name Type of Meeting
9-Feb-2021 Edelweiss India Annual e-Conference2021 Tele/Video Conference
25-Feb-2021 IIFL Securities – Global InvestorConference

The schedule of the above mentioned meeting is subject to change and the change may occur due to exigencies on the part of Investor/ Analyst/ Company.

Yours truly,

==> picture [217 x 108] intentionally omitted <==

Factory & Regd. Office: Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal, Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Tel: +91-40-30510999 Fax; +91-40-30510800, email: [email protected] | www.glandpharma.com CIN: U24239TG1978PLC002276